A single dose of LSD can treat anxiety and depression for months, study shows

By Jon Hamilton

Published September 4, 2025 at 5:24 PM EDT

A new study finds that a single dose of LSD can ease a person's anxiety for months. This could give legitimacy to research on a range of psychedelics.

Jon Hamilton

Jon Hamilton is a correspondent for NPR's Science Desk. Currently he focuses on neuroscience and health risks.

See stories by Jon Hamilton

Support nonprofit, fact-based public service journalism

WEKU depends on support from those who view and listen to our content. There's no paywall here. Please support WEKU with your donation.

Contribute now

Related Content

K-pop boy band Stray Kids' album 'Karma' debuts at the top of the Billboards

Stephen Thompson

KPop Demon Hunters is still doing great on the Billboard charts. But another K-pop juggernaut debuts in the top spot for albums. That'd be the boy band Stray Kids, whose new album is titled Karma.
Maine residents hold a party to toast with their future neighbors... at the cemetery

Grace Benninghoff

In Weld, Maine, anyone who owns a plot at the Mountain View Cemetery is invited to a yearly gathering at the undertaker's home -- a chance to "get to know who you'll spend eternity with," locals say.
This week in science: Recycling innovation, scrolling dangers and the inside of Mars

Regina G. Barber

NPR's Emily Kwong and Regina Barber of Short Wave talk about an innovation in plastic recycling, the link between smartphones and hemorrhoids and what Mars' structure and ice cream have in common.
States prepare alternative COVID vaccine plans to maintain access

Pien Huang

States vary in their policies for COVID vaccines this fall, which could affect availability and put many at odds with the Centers for Disease Control and Prevention.
The U.S. government is taking a stake in Intel. It's rare — but not unprecedented

John Ruwitch

The Trump administration last month took a 10% stake in chipmaker Intel. It's not the first time the government has taken a stake in a U.S. firm, but the circumstances are unusual and the desired outcome -- renewed American prowess in chipmaking -- is far from guaranteed.